While predefined clinical endpoints did not show significant differences between the relatively small groups of MS patients treated with HspB5 or placebo, repeated administration, particularly of the lower doses of HspB5, led to a progressive decline in MS lesion activity monitored by magnetic resonance imaging, a trend not observed in the placebo group. This evidence concerns the gene CRYAB and myeloid sarcoma.